Adagene completes enrollment in phase 2 trial of muzastotug

Adagene completed enrollment of 60 patients in its randomized Phase 2 dose-optimization trial of muzastotug plus KEYTRUDA for late-line microsatellite stable colorectal cancer without liver metastases. Initial results are expected in the first half of 2027; the trial compares two dose regimens, with overall response rate as its primary endpoint. The milestone advances development, but no efficacy results are yet available.

Analysis

Enrollment completion removes a trial-execution overhang for Adagene, but it does little to resolve the core risk: whether this regimen can generate a clinically meaningful signal in a difficult, narrowly defined colorectal-cancer population. The 60-patient dose-optimization study is principally a regimen-selection step, not a clean efficacy read-through; avoid treating a favorable response-rate result as proof of Phase 3 success, particularly because the later pivotal test is based on overall survival. FDA alignment on design lowers some regulatory-path uncertainty, not the probability of clinical success.

For ADAG, the value catalyst is distant (initial results expected in H1 2027), leaving funding runway, dilution, and the terms and scale of Sanofi’s investment more important near-term variables than this enrollment milestone. Verify cash runway and investment terms before assigning value to reduced financing risk. Sanofi’s participation is a modest validation signal, not evidence of efficacy or a disclosed commitment to commercialize. MRK’s role as the pembrolizumab provider does not establish meaningful incremental economics; absent disclosed terms, this is not an MRK earnings catalyst.

The contrarian read is that a positive headline may be overvalued relative to the information gained: randomization between two dosing schedules can optimize exposure, but cannot by itself establish benefit versus standard care. Conversely, the narrow no-liver-metastases population may be easier to study than broader MSS disease, while limiting the eventual addressable market. The key reversal points are weak response durability, adverse safety findings, runway deterioration, or Phase 3 design/operational changes.

Key Decisions for Investors

• ADAG: Do not chase the enrollment-completion headline as an efficacy catalyst. For event-driven exposure, keep sizing explicitly small and treat it as a long-dated clinical option; the key data window is H1 2027, with substantial downside if the signal is weak or the program requires additional capital.
• Near term, put ADAG on a watchlist rather than initiating a directional trade until cash runway, Sanofi investment amount/terms, and any near-term financing needs are verified. A shortened runway or equity raise would falsify the reduced-financing-risk interpretation.
• Use the forthcoming dose-optimization readout to assess response rate alongside duration of response and safety—not response rate alone. Weak durability, toxicity, or no clear dose rationale would undermine the Phase 3 thesis even if initial responses occur.
• No incremental MRK or SNY position is warranted on this update alone: the disclosed information does not establish material new revenue for Merck or a quantified change in Sanofi’s risk exposure.